For example, radiomic profiles linked to PD-L1 (programmed death ligand 1) expression, tumor-infiltrating lymphocytes (TILs), or EGFR mutation status (common in NSCLC-derived metastases) may predict response to anti-PD-1/PD-L1 inhibitors or EGFR tyrosine kinase inhibitors (TKIs) [124]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.